"Patients whose CSCC is at a high risk of recurrence following surgery and radiation often have the poorest outcomes. “Many patients who undergo surgical resection of their CSCC are later found, on full pathological evaluation, to be at high risk of recurrence. The safety profile of Libtayo as adjuvant treatment of patients with CSCC at high risk of recurrence after surgery and radiation is consistent with the known safety profile for Libtayo monotherapy in advanced cancers. The company has launched Libtayo Surround™, which offers financial and educational resources to help support patients throughout their treatment journey. Your healthcare provider may also need to delay or completely stop treatment with LIBTAYO if you have severe side effects.